Interferon in metastatic renal cell carcinoma.

摘要: Metastatic renal cell carcinoma (MRCC) represents an immunoresponsive malignancy in individual patients. Interferons (IFNs) have thus been broadly investigated this cancer type, with the most commonly used being recombinant IFN-alpha. The average response rate is 15%, a duration of 4 to 6 months. Complete responses are rare (< or =5%), but may be long-lasting. Responses seen predominantly lung and lymph node metastases. Subcutaneous (SC) intramuscular (IM) doses 9 10 x 10(6) U/d 18 U thrice weekly often used. Flu-like symptoms (fever, myalgia, asthenia) occur almost all patients treated IFN-alpha dose-limiting. combination vinblastine not superior IFN monotherapy. Phase III studies demonstrated modest survival benefit for therapy as compared placebo-equivalent treatment, gain 3 7 Predictive beneficial outcome excellent performance status, low sedimentation rate, no weight loss, long interval between initial diagnosis start treatment. significance nephrectomy currently phase studies. IFN-gamma has major therapeutic role MRCC. IFN-beta "natural IFN" equally effective In conclusion, standard treatment MRCC who candidates systemic therapy. Any IFN-alpha-containing investigational (eg, interleukins retinoids).